The organisation requests approval of measures allowing manufacturers to continue supplying medicines to Northern Ireland from Great Britain, maintain single packaging, and choose between EU and UK authorisation procedures. They emphasise the importance of MHRA issuing UK-wide marketing authorisations and clarity on packaging requirements. This would avoid costly relocation of testing facilities and separate packaging for different markets.